

CITATION REPORT

List of articles citing

Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck

DOI: 10.1111/j.1464-410x.1975.tb03947.x

British Journal of Urology, 1975, 47, 193-202.

Source: <https://exaly.com/paper-pdf/12163063/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
428	Functions Mediated by α -Adrenoceptors. 1991 , 8, 115-179		7
427	Sympathetic activity in the proximal urethra in patients with urinary obstruction. 1976 , 115, 545-7		88
426	Adrenergic and cholinergic stimulation and blockade of the human bladder base. 1976 , 116, 174-5		40
425	The use of alpha-adrenergic blockers in benign prostatic obstruction. <i>British Journal of Urology</i> , 1976 , 48, 255-63		68
424	The Use of Alpha-adrenergic Blockers in Benign Prostatic Obstruction. <i>British Journal of Urology</i> , 1976 , 48, 255-263		201
423	The phentolamine test in neurogenic bladder dysfunction. 1977 , 117, 481-5		35
422	Adrenoceptor and cholinceptor mediated responses of the isolated human urethra. 1977 , 11, 97-102		74
421	Uro pharmacology: part VI. Parasympathetic depressants. 1977 , 10, 503-10		21
420	Dynamics of acute retention in prostatic patient and role of adrenergic receptors. 1977 , 9, 399-403		58
419	Uro pharmacology: IV. Parasympathomimetic drugs. 1977 , 9, 474-7		2
418	The importance of adrenergic receptors in disorders of micturition. 1977 , 3, 1-6		17
417	Effects of prostaglandins on the isolated human bladder and urethra. 1977 , 100, 165-71		75
416	Adrenergic and Cholinergic Nerves of the Human Urethra and Urinary Bladder. A histochemical study. 1977 , 99, 345-52		143
415	Post-prostatectomy incontinence. 1978 , 6, 113-8		4
414	Alpha-adrenergic agents in urinary disorders of the proximal urethra. Part I. Sphincteric incontinence. <i>British Journal of Urology</i> , 1978 , 50, 332-5		61
413	A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. <i>British Journal of Urology</i> , 1978 , 50, 551-4		245
412	Insulin production by pancreatic islets of obese-hyperglycemic mice cultured for one week in different glucose concentrations. 1978 , 104, 377-85		26

411	Uropharmacology: VIII. Sympathomimetic agents. 1978 , 11, 536-41		6
410	Innervation of the ventral prostate of the rat. 1979 , 154, 231-43		47
409	From intermittent catheterisation to catheter freedom via urodynamics: a tribute to Sir Ludwig Guttmann. 1979 , 17, 73-85		5
408	Uropharmacology: XI. Adrenergic-blocking agents and drugs affecting catecholamine binding and release. 1979 , 13, 693-700		4
407	The action of bromocriptine on human detrusor muscle. 1980 , 8, 207-9		4
406	The pharmacological action of bromocriptine on the human prostate. 1980 , 8, 25-8		9
405	Urethro-vesical function during spinal shock. 1980 , 8, 53-65		17
404	The autonomic innervation of the human urinary bladder, bladder neck and urethra: a histochemical study. 1980 , 198, 439-47		84
403	Clinical and urodynamic assessment of alpha-adrenolytic therapy in patients with neurogenic bladder function. 1980 , 18, 229-40		13
402	Effects of Phenoxybenzamine on Bladder Neck Opening ¹ . <i>Journal of the Royal Society of Medicine</i> , 1980 , 73, 345-347	2,3	4
401	Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases. 1981 , 17, 542-6		82
400	Urethral pressure profilometry in the preoperative assessment for prostatectomy. 1981 , 126, 89-91		11
399	The alpha-adrenergic blocking effect of prazosin on the human prostate. 1981 , 9, 17-20		51
398	Influence of the adrenergic nervous system on the lower urinary tract and its clinical implications. 1982 , 4, 37-43		0
397	Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. 1982 , 128, 836-9		187
396	Il Ruolo Della Fenossibenzamina Nel Trattamento Dell'Adenoma Della Prostata. 1982 , 49, 229-232		2
395	Effects of adrenergic drugs on miniature contractions of isolated dog urinary bladder. 1982 , 8, 37-41		1
394	Bladder outflow obstruction treated with phenoxybenzamine. <i>British Journal of Urology</i> , 1982 , 54, 527-30		101

393	Influence of the sympathetic nervous system on the lower urinary tract and its clinical implications. 1982 , 1, 129-148	16
392	Symptomatic treatment of benign prostatic obstruction with nicergoline: a placebo controlled clinical study and urodynamic evaluation. 1982 , 10, 131-4	18
391	Influence of the sympathetic nervous system on lower urinary tract in man. 1983 , 2, 3-26	33
390	Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy. A controlled study. 1983 , 21, 474-8	36
389	Effects of prazosin in patients with benign prostatic obstruction. 1983 , 130, 275-8	207
388	Valutazione Uroflussometrica Dopo Trattamento Combinato Confenossibenzamina E Cloruro Di Betanecolo. 1983 , 50, 870-878	
387	Studio Randomizzato in Doppio Cieco Con Prazosin E Placebo Nel Trattamento Dell'Adenoma Prostatico. 1983 , 50, 122-130	
386	Alpha-blockers in the treatment of benign prostatic hypertrophy: physiological basis and review of the problem. 1984 , 10, 306-10	11
385	La Nicergolina Nel Trattamento Della Ipertrofia Semplice Della Prostata. 1984 , 51, 823-824	
384	Nicergoline in the treatment of neuropathic bladder dysfunction: a preliminary report. 1984 , 22, 216-24	3
383	The effect of nicergoline on the lower urinary tract muscle. 1984 , 12, 287-90	7
382	Primary bladder neck obstruction. 1984 , 2, 191-195	30
381	Characterization and localization of the muscarinic cholinergic receptor in human prostatic tissue. 1984 , 132, 397-402	56
380	Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. 1984 , 132, 1226-9	140
379	Acute retention of urine due to benign prostatic obstruction treated with alpha-adrenergic blockers. 1984 , 39, 114-5	5
378	Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. 1985 , 134, 1291-8	160
377	alpha 1-Adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. 1985 , 330, 16-21	56
376	Valutazione Clinica E in Vitro Degli Effetti Dell'Alfa-Bloccante Nicergolina Sul Collo Vescicale. 1985 , 52, 119-125	

375	In vitro characterization of the alpha-adrenoceptors in human prostate. 1985 , 107, 111-7	117
374	Capsular influence on benign prostatic hyperplasia. 1986 , 28, 347-50	8
373	Prevention of prolonged voiding problems after unexpected postoperative urinary retention: comparison of phenoxybenzamine and carbachol. 1986 , 136, 1254-7	30
372	The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. 1986 , 136, 1-4	236
371	Alpha 2 adrenergic receptors in hyperplastic human prostate: identification and characterization using [3H] rauwolscine. 1986 , 135, 1038-42	59
370	Acute urinary retention secondary to benign prostatic hyperplasia. Effect of alpha-adrenergic blockade. 1986 , 41, 430-1	
369	The alpha-1 Adrenergic Receptors. 1987 ,	8
368	Alpha 1 adrenergic receptors in canine lower genitourinary tissues: insight into development and function. 1987 , 138, 979-83	34
367	Identification and characterization of alpha 1 adrenergic receptors in the canine prostate using [125I]-Heat. 1987 , 138, 1336-9	18
366	Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. 1987 , 138, 158-60	36
365	Alpha 2 adrenergic receptors in canine prostate: biochemical and functional correlations. 1987 , 137, 565-70	29
364	Phenoxybenzamine in prostatic hypertrophy. A double-blind study. <i>British Journal of Urology</i> , 1987 , 59, 63-5	17
363	Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. <i>British Journal of Urology</i> , 1987 , 60, 136-42	212
362	Effect of prazosin on tissue of the human prostate with benign hypertrophy. 1988 , 106, 1129-1130	
361	Effects of cimetidine, progesterone, cannitracin and tolazoline on the weight and DNA content of the testosterone-induced hyperplastic prostate of the rat. 1988 , 16, 363-6	1
360	Electrical and mechanical properties of the capsular smooth muscles of the rabbit prostate in relation to the actions of the alpha 1-adrenoceptor blocker, YM-12617. 1988 , 93, 702-14	17
359	The Pharmacology of Peripheral α and β -Adrenoceptors. 1988 , 7,	3
358	Benign prostatic hyperplasia. Universal problem among aging men. 1988 , 83, 79-85	10

357	Alpha-adrenergic blockers. 1988 , 72, 427-40	9
356	Dynamic study of nervous control on prostatic contraction and fluid excretion in the dog. 1988 , 140, 1567-70	27
355	The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain. 1988 , 140, 664-7	33
354	The effect of electrocautery on neurotransmitter receptor binding assays in the canine prostate. 1988 , 140, 668-71	8
353	Surgical treatment of the incontinent female patient with myelomeningocele. 1988 , 139, 524-7	28
352	Electrical and mechanical activity of rabbit prostate smooth muscles in response to nerve stimulation. 1989 , 419, 651-63	21
351	Regional distribution of opioidergic nerves in human and canine prostates. 1989 , 14, 279-88	13
350	Contractile properties of human prostate adenomas and the development of infravesical obstruction. 1989 , 15, 105-14	73
349	Urodynamic effect of acute alpha-receptor blockade in patients with bladder neck dysfunction. 1989 , 23, 15-20	1
348	An in vivo evaluation of alpha adrenergic receptors in canine prostate. 1989 , 141, 1230-3	12
347	Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. 1989 , 142, 438-44	79
346	A histochemical and immunohistochemical study of the autonomic innervation of the lower urinary tract of the female pig. Is the pig a good model for the human bladder and urethra?. 1989 , 141, 414-22	91
345	Effects of prazosin HCl on the urethral pressure profile in patients with benign prostatic hyperplasia. 1990 , 45 Suppl 1, 30-5	2
344	This month in investigative urology: alpha adrenergic innervation of the prostate: insights into pharmacotherapy of BPH. 1990 , 143, 590-1	15
343	Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. 1990 , 3, 1-7	90
342	Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. 1990 , 3, 85-93	57
341	Trattamento Sintomatico Dell'Ipertrofia Prostatica Benigna Con Alfuzosine: Esperienza clinica su 102 pazienti.. 1990 , 57, 29-34	
340	Medical management of benign prostatic hyperplasia. 1990 , 36, 5-12	10

339	Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. 1991 , 337, 1457-61	223
338	Muscarinic receptors in diabetic rat prostate. 1991 , 42 Suppl, S113-9	24
337	Antispasmodic effects of flavoxate, MFCA, and REC 15/2053 on smooth muscle of human prostate and urinary bladder. 1991 , 37, 390-4	7
336	Identification of the causes of persistent hyperuricaemia. 1991 , 337, 1461-3	29
335	Too stringent patient selection criteria in a clinical trial of alpha-blockers reduce the value of the results. 1991 , 20, 175-8	1
334	Functions Mediated by α -Adrenoceptor Activation. 1991 , 7, 173-209	1
333	The innervation of the human prostate gland--the changes associated with benign enlargement. 1991 , 146, 1637-44	64
332	Alpha 1 blockers. Safe, effective treatment for hypertension. 1991 , 89, 89-92, 95-8, 103-6, passim	4
331	Comparison of alpha 1 adrenoceptors in the prostate capsule of men with symptomatic and asymptomatic benign prostatic hyperplasia. <i>British Journal of Urology</i> , 1991 , 67, 493-8	23
330	Indoramin in the treatment of prostatic bladder outflow obstruction. <i>British Journal of Urology</i> , 1991 , 67, 499-501	23
329	In vitro and in vivo studies on the effects of the alpha-adrenoceptor blocker IP/66 (1-(2-ethoxy-2-(3?-pyridyl)ethyl)-4-(2?-methoxy-phenyl)piperazine) on urethral tone in rats. 1991 , 23, 35-46	1
328	Beta adrenergic receptor alterations in diabetic rat prostate: effects of insulin and dietary myoinositol. 1991 , 19, 121-31	20
327	Alpha-adrenoceptor blockers in the treatment of benign prostatic hyperplasia. 1991 , 9, 36	13
326	Alpha-Blockade for Benign Prostatic Hyperplasia. 1991 , 5, 83-87	4
325	Effects of Naftopidil (KT-611) on Lower Urinary Tract Function in Patients with Benign Prostatic Hyperplasia. 1992 , 6, 445-448	1
324	Medical treatment for benign prostatic hyperplasia. 1992 , 304, 1198-9	14
323	Benign prostatic hyperplasia: antecedents and natural history. 1992 , 14, 131-53	145
322	A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia. 1992 , 107, 803-7	41

321	Binding characteristics of naftopidil and alpha 1-adrenoceptor antagonists to prostatic alpha-adrenoceptors in benign prostatic hypertrophy. 1992 , 50, 127-35	24
320	Developments in the control of testicular function. 1992 , 6, 451-83	20
319	Oxytocin and related peptides elicit contractions of prostate and seminal vesicle. 1992 , 652, 474-7	5
318	Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate. 1992 , 216, 311-3	35
317	Benign prostatic hyperplasia: pathogenesis and the role of medical management. 1992 , 2, 1-23	3
316	Alpha 1-adrenoceptor properties of terazosin HCl and its enantiomers in the human prostate and canine brain. 1992 , 20, 159-65	7
315	Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group. <i>British Journal of Urology</i> , 1992 , 70, 58-64	44
314	Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. <i>British Journal of Urology</i> , 1992 , 70 Suppl 1, 2-9	23
313	Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. <i>British Journal of Urology</i> , 1992 , 70 Suppl 1, 10-6	22
312	Neurogenic bladder in lower motor neuron lesion: Long-term assessment. 1992 , 11, 509-517	6
311	Role of intracellular Ca ²⁺ stores in smooth muscle contractions of the guinea pig vas deferens. 1993 , 21, 319-23	7
310	Urinary Flow Rates in Patients with Benign Prostatic Hypertrophy following Treatment with Alfuzosin. <i>British Journal of Urology</i> , 1993 , 72, 58-64	
309	Quantitative analysis of adrenergic alpha-1 and alpha-2 receptors in human prostatic urethral tissue. <i>British Journal of Urology</i> , 1993 , 72, 68-73	12
308	Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. <i>British Journal of Urology</i> , 1993 , 72, 922-7	47
307	Reflections and suggestions on the nomenclature of the prostate. 1993 , 15, 325-32	9
306	Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists. 1993 , 68, 670-9	32
305	Medical therapy for benign prostatic hyperplasia. 1993 , 42, 483-501	62
304	Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. 1993 , 27, 39-44	67

303	Nephrology and Urology in the Aged Patient. 1993 ,	
302	The M3-muscarinic cholinceptor subtype in rat prostate and its down regulation by aging. 1993 , 61, 319-24	18
301	Improving effects of FG-7080, a serotonin reuptake inhibitor, on scopolamine-induced performance deficits of memory tasks in rats. 1993 , 62, 203-6	5
300	Clinical effect of alpha-1 antagonism by terazosin on external and internal urinary sphincter function. 1993 , 16, 207-14	31
299	Pelvic plexus denervation in rats causes morphologic and functional changes of the prostate. 1993 , 150, 215-8	34
298	Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. 1993 , 150, 546-51	282
297	Influence of alpha-receptor blockade on the time-dependent change in the effect of furosemide. 1993 , 62, 403-5	4
296	Posthernioplasty urinary retention: a noninvasive work-up for prediction. 1993 , 51, 243-5	12
295	Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group. 1993 , 24 Suppl 1, 28-33	13
294	Receptorial characterization of adrenergic neuroregulation of micturition, ejaculation and erection. An up-to-date review. 1994 , 61, 116-122	
293	Benign Prostatic Hyperplasia. 1994 , 23, 795-807	14
292	29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. 1994 , 28, 77-82	62
291	Effects of preoperative methoxamine on blood loss and haemodynamic variables during transurethral prostatic resection under spinal anaesthesia. 1994 , 73, 624-7	1
290	Nitric oxide synthase activity in the human urogenital tract. 1994 , 22, 287-90	79
289	G-proteins in alpha 1-adrenoceptor mediated prostatic smooth muscle contraction. 1994 , 22, 143-6	15
288	Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. 1994 , 25, 46-52	29
287	Effect of terazosin on urine storage and voiding in the aging male with prostatism. 1994 , 13, 1-12	22
286	Multidirectional contraction of human hypertrophied prostate. 1994 , 25, 1459-64	10

285	Alpha-adrenoceptors. 1994 , 61, 1-64	118
284	Alpha 1A-adrenoceptor subtype mediates contraction of the rat urethra. 1994 , 14, 375-81	14
283	Rationale for the use of alpha-blockers in the treatment of benign prostatic hyperplasia (BPH). 1994 , 1, 203-11	14
282	Effects of dicentrine, a novel alpha 1-adrenoceptor antagonist, on human hyperplastic prostates. 1994 , 252, 29-34	21
281	Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. 1994 , 113, 723-8	95
280	Alpha 1-adrenoceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists. 1994 , 54, 1845-54	45
279	Benign prostatic hyperplasia. Current pharmacological treatment. 1994 , 47, 66-81	63
278	Obesity and benign prostatic hyperplasia. 1994 , 140, 989-1002	182
277	The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia. 1995 , 65, 35-9	9
276	Khat chewing and bladder neck dysfunction. A randomized controlled trial of alpha 1-adrenergic blockade. <i>British Journal of Urology</i> , 1995 , 75, 597-8	27
275	Pharmacological antagonism of α_1 -adrenergic agonist induced increases in canine intraurethral pressure in vivo. 1995 , 34, 267-275	19
274	Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group. 1995 , 27, 128-34	13
273	Benign prostatic hyperplasia. Medical and minimally invasive treatment options. 1995 , 332, 99-109	185
272	Pathogenesis and medical management of benign prostatic hyperplasia. 1995 , 6, 128-32	7
271	Characterization and localization of nitric oxide synthase in the human prostate. 1995 , 45, 435-9	101
270	Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype. 1995 , 115, 781-6	126
269	Alpha-Blockade in the Treatment of Symptomatic Benign Prostatic Hyperplasia. 1995 , 154, 923-934	80
268	Localization of the alpha 1A-Adrenoceptor in the Human Prostate. 1995 , 154, 2096-2099	46

267	Doxazosin for the Treatment of Benign Prostatic Hyperplasia in Patients with Mild to Moderate Essential Hypertension: A Double-Blind, Placebo-Controlled, Dose-Response Multicenter Study. 1995 , 154, 110-115		155
266	Effects of androgen deprivation on prostate alpha 1-adrenergic receptors. 1996 , 48, 335-41		16
265	A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. 1996 , 47, 335-42		53
264	Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. 1996 , 118, 1403-8		74
263	The alpha-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate. 1996 , 313, 135-43		18
262	Pharmacological Characterization of the Isolated Canine Prostate. 1996 , 155, 1758-1761		27
261	Prostatism: benign prostatic hyperplasia. <i>Urologic Clinics of North America</i> , 1996 , 23, 75-86	2.9	18
260	Prostate Selectivity of Alpha-Blockers: From Receptor Biology to Clinical Medicine. 1996 , 29, 12-16		6
259	Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs. 1996 , 53, 356-68		25
258	Recent advances in the identification of alpha1- and alpha2-adrenoceptor subtypes: therapeutic implications. 1997 , 6, 367-87		44
257	Benign prostatic hyperplasia. Practical treatment guidelines. 1997 , 10, 349-66		49
256	Influence of prostate size on terazosin efficacy. 1997 , 4, 358-61		5
255	Responsiveness of smooth muscle in the lower urinary tract of rabbits to various agonists. 1997 , 28, 629-31		9
254	Phytopharmaceutical and synthetic agents in the treatment of benign prostatic hyperplasia (BPH). 1997 , 3, 309-13		6
253	Prostatic alpha 1-adrenoceptors and uroselectivity. 1997 , 30, 202-15		113
252	Intrinsic and extrinsic factors controlling benign prostatic growth. 1997 , 31, 131-8		63
251	Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. 1997 , 33, 55-9		73
250	Functional property, norepinephrine content and morphometric findings in human hyperplastic prostate. 1997 , 33, 183-7		4

249	Alpha-adrenergic approach in the medical management of benign prostatic hyperplasia. 1997 , 17, 523-35	23
248	The adrenergic, cholinergic and NANC nerve-mediated contractions of the female rabbit bladder neck and proximal, medial and distal urethra. 1998 , 123, 1517-24	14
247	Formative years of the Urodynamics Society: reminiscences. 1998 , 17, 159-74	3
246	Evaluation of histological structure and its effect on the distribution of alpha1-adrenoceptors in human benign prostatic hyperplasia. 1998 , 81, 388-93	1
245	Characterization of the muscarinic receptor mediating contraction of the dog prostate. 1998 , 18, 205-11	15
244	Pharmacology of neurotransmission to the smooth muscle of the rat and the guinea-pig prostate glands. 1998 , 18, 349-56	41
243	INDUCTION OF PROSTATE APOPTOSIS BY DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA. 1998 , 159, 1810-1815	121
242	alpha 1-ADRENERGIC RECEPTOR SUBTYPES IN HUMAN DETRUSOR. 1998 , 160, 937-943	218
241	4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperaziny]-6, 7-dimethoxyquinazoline (L-765,314): a potent and selective alpha1b adrenergic receptor antagonist. 1998 , 41, 1205-8	53
240	Overview of alpha-blocker therapy for benign prostatic hyperplasia. 1998 , 51, 38-45	50
239	Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. II. Pathology and pathophysiology. 1998 , 51, 73-82	67
238	Alpha1-adrenoceptors in testosterone-induced prostatic hypertrophy. 1998 , 341, 119-26	7
237	The medical management of lower urinary tract symptoms and benign prostatic hyperplasia. <i>Urologic Clinics of North America</i> , 1998 , 25, 555-69, vii	2.9 8
236	Properties of alpha-1-adrenergic receptors in the rat prostate: effect of experimental diabetes. 1998 , 61, 147-53	13
235	Medical therapy and quality of life. 1998 , 34 Suppl 2, 10-7; discussion 46	16
234	The concept of uroselectivity. 1998 , 33 Suppl 2, 7-11	31
233	Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade. <i>British Journal of Urology</i> , 1998 , 81 Suppl 1, 34-47; discussion 64-6	53
232	History and nomenclature of alpha1-adrenoceptors. 1999 , 36 Suppl 1, 2-6	39

231	Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. 1999 , 2, 110-119	21
230	alpha(1L)-adrenoceptors mediate noradrenaline-induced contractions of the guinea-pig prostate stroma. 1999 , 384, 25-30	14
229	Induction of Prostate Apoptosis in Response to α -Adrenoceptor Antagonists: Therapeutic Significance in Benign Prostatic Hyperplasia and Prostate Cancer. 1999 , 1, 73-81	
228	Prostate stroma: physiology. 1999 , 38, 60-72	56
227	Treatment of benign prostatic enlargement with alpha-blockers: an updated review. 1999 , 203, 9-13	2
226	The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. 1999 , 53, 121-5	100
225	Benign prostatic hyperplasia: an overview. 1999 , 53, 1-6	97
224	Alpha-blockers in benign prostatic hyperplasia. 1999 , 54, 773-5	15
223	NEW alpha 1-ADRENOCEPTOR ANTAGONIST, JTH-601, SHOWS MORE THAN 10 TIMES HIGHER AFFINITY FOR HUMAN PROSTATES THAN ARTERIES. 1999 , 161, 1350-1354	13
222	Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. 1999 , 57, 9-17	46
221	Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. 2000 , 9, 42-6	38
220	Clinical perspective on apoptosis in the management of the BPH patient. 2000 , 45, 47-50	2
219	alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. 2000 , 85 Suppl 2, 6-11	76
218	Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. 2000 , 86 Suppl 2, 11-20; discussion 20-2	38
217	Acute urinary retention. 2000 , 85, 186-201	103
216	The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. 2000 , 20, 193-206	91
215	Cholinergic facilitation of neurotransmission to the smooth muscle of the guinea-pig prostate gland. 2000 , 130, 1013-20	17
214	Alpha 1-adrenergic receptor regulation: basic science and clinical implications. 2000 , 88, 281-309	188

213	Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. 2000 , 394, 123-30	9
212	Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs. 2000 , 1, 89-96	15
211	The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasia. 2000 , 1, 97-102	7
210	Alpha-blockers: an effective treatment for prostatitis?. 2000 , 1, 148-54	5
209	A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. 2000 , 17, 287-300	12
208	Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group. 2000 , 37, 680-6	6
207	Alterations of the Calcium Concentration in Cultured Smooth Muscle Cells of the Lower Urinary Tract following Pharmacological Stimulation. 2000 , 31, 41-48	1
206	TISSUE SELECTIVITY OF KMD-3213, AN α_1 -ADRENOCEPTOR ANTAGONIST, IN HUMAN PROSTATE AND VASCULATURE. 2000 , 164, 578-583	62
205	Muscarinic Receptor Agonists and Antagonists. 2001 , 6, 142-193	52
204	alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. 2001 , 165, 38-41	51
203	CHARACTERIZATION AND FUNCTIONAL RELEVANCE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOENZYMES OF THE HUMAN PROSTATE. 2001 , 166, 2484-2490	163
202	Alpha adrenoceptor antagonists in the year 2000: is there anything new?. 2001 , 11, 9-16	26
201	Lack of neuropeptide Y receptor detection in human bladder and prostate. 2000 , 85, 918-24	14
200	Doxazosin: a new cytotoxic agent for prostate cancer?. 2000 , 85, 672-5	18
199	The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. 2001 , 88 Suppl 2, 27-34; discussion 49-50	68
198	The efficacy of alfuzosin treatment in patients with prostatism. 2001 , 33, 493-7	5
197	Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. 2001 , 32, 423-32	18
196	Classical vs reverse pharmacology in drug discovery. 2001 , 88 Suppl 2, 7-10; discussion 49-50	39

195	alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia. 2002 , 65, 119-28	36
194	The use of alpha-adrenoceptor antagonists in lower urinary tract disease. 2002 , 3, 167-72	20
193	Method for simultaneous recording of the prostatic contractile and urethral pressure responses in anesthetized rats and the effects of tamsulosin. 2002 , 90, 281-90	13
192	THE ROLE OF M2 MUSCARINIC RECEPTOR SUBTYPES IN MEDIATING CONTRACTION OF THE PIG BLADDER BASE AFTER CYCLIC ADENOSINE MONOPHOSPHATE ELEVATION AND/OR SELECTIVE M3 INACTIVATION. 2002 , 167, 397-401	38
191	Fisiologĳ de la prĳtata. 2002 , 34, 1-6	
190	Hipertrofia benigna de la prĳtata. 2002 , 34, 1-14	
189	Cholinergic innervation and function in the prostate gland. 2002 , 94, 93-112	79
188	Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. 2002 , 5, 88-95	61
187	Quantitative determination of a selective alpha-1a receptor antagonist in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. 2002 , 775, 133-42	7
186	Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. 2003 , 22, 338-42	30
185	Afferent fibers of the pudendal nerve modulate sympathetic neurons controlling the bladder neck. 2003 , 22, 597-601	49
184	Tratamiento del paciente hipertenso con hiperplasia benigna de prĳtata. 2003 , 20, 395-402	
183	[Categorization of adrenergic alpha 1 receptors in detrusor of patients with obstructive BPH. Initial study on experimental animal model]. 2003 , 27, 684-91	2
182	Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. 2003 , 62, 1-9	41
181	Alfuzosin for the management of benign prostate hyperplasia. 2003 , 4, 2057-63	7
180	Medical management of benign prostatic hyperplasia--are two drugs better than one?. 2003 , 349, 2449-51	26
179	Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. 2003 , 60, 1426-39	9
178	Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. 2004 , 73, 125-9	7

177	Alpha-blocker test: alternative to pressure-flow study of bladder outlet obstruction and detrusor contractility in patients without an enlarged prostate. 2004 , 11, 20-5	2
176	Effects of steroids on oxytocin secretion by the human prostate in vitro. 2004 , 27, 12-8	16
175	Origin of the primary efferent neurons projecting to the prostate of the dog. 2004 , 186, 349-56	2
174	Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate. 2004 , 318, 375-82	39
173	Inhibitory effect of buflomedil on prostate alpha1A adrenoceptor in the Wistar rat. 2004 , 367, 224-7	1
172	Stress, hostility, and disease parameters of benign prostatic hyperplasia. 2005 , 67, 476-82	12
171	Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. 2005 , 96, 581-6	65
170	Current models of human prostate contractility. 2005 , 32, 797-804	8
169	Benign prostatic hyperplasia: age-related tissue-remodeling. 2005 , 40, 121-8	204
168	Evaluation of the mouse prostate as a suitable model for the study of human prostate function. 2005 , 51, 41-50	13
167	Alpha-adrenergic blockers in prostatism. 1977 , 64, 756-7	45
166	Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. 2005 , 174, 1743-8	43
165	"Ejaculatory disorders and alpha1-adrenoceptor antagonists therapy: clinical and experimental researches". 2006 , 4, 31	10
164	In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. 2006 , 67, 1292-7	19
163	Bladder drainage and glandular epithelial morphometry of the prostate in benign prostatic hyperplasia with severe symptoms. 2006 , 32, 211-5	9
162	Management of benign prostate hyperplasia: an overview of alpha-adrenergic antagonist. 2006 , 29, 1554-8	8
161	The role of alfuzosin in the treatment of benign prostate hyperplasia and acute urinary retention. 2006 , 2, 363-369	
160	The management of benign prostatic obstruction: a voice from the Third World. 2006 , 97, 671-2	2

159	Management of acute urinary retention. 2006 , 97 Suppl 2, 16-20; discussion 21-2	70
158	The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. 2006 , 97, 727-33	58
157	Central obesity as a risk factor for prostatic hyperplasia. 2006 , 14, 172-9	74
156	Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. 2006 , 147 Suppl 2, S88-119	319
155	Differentiated rabbit prostatic stromal cells in primary culture display functional alpha1A-adrenoceptors. 2006 , 25, 168-78	2
154	Oxytocin--its role in male reproduction and new potential therapeutic uses. 2006 , 12, 437-48	88
153	Oxytocin and the human prostate in health and disease. 2007 , 263, 253-86	8
152	Alpha blockers for removal of urethral catheter after acute urinary retention in men. 2007 ,	
151	cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy. 2007 , 67, 1397-410	24
150	Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2008 , 6, 24-30	
149	Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2008 , 9, 295-301	1
148	Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. 2008 , 101, 1111-8	48
147	Comparisons of the responses of anterior and posterior human adult male bladder neck smooth muscle to in vitro stimulation. 2008 , 102, 1737-42	1
146	Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. 2008 , 28, 356-65	15
145	In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract. 2008 , 580, 394-400	8
144	Cholinergic innervation and muscarinic receptors in the human prostate. 2008 , 54, 326-34	48
143	Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction. 2008 , 68, 209-29	13
142	alpha-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. 2008 , 101, 319-24	82

141	The Reten-World survey of the management of acute urinary retention: preliminary results. 2008 , 101 Suppl 3, 27-32		42
140	The role of combination medical therapy in benign prostatic hyperplasia. 2008 , 20 Suppl 3, S33-43		27
139	Benign prostatic hyperplasia: transcatheter arterial embolization as potential treatment--preliminary study in pigs. 2008 , 246, 783-9		87
138	Predictive Factors for Recovery from Acute Urinary Retention after Non-Urogenital Surgery. 2009 , 50, 976		2
137	Silodosin: an orally active selective α_1 -adrenoceptor antagonist for benign prostatic hyperplasia. 2009 , 5, 459-473		2
136	Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg. 2009 , 82, 136-42		7
135	The In Vivo Effects of autonomic drugs and electroejaculation on prostate gland contractility in the rat/Der in-vivo-Einfluß von autonomen Medikamenten und der Elektroejakulation auf die Prostata-Kontraktilität der Ratte. 2009 , 20, 289-294		1
134	The Decline of TURP--An Irish Experience. 2009 , 2, 185-190		1
133	Urothelial α_1 D Receptor is Predominantly Involved in the Adrenergic Facilitation of Micturition Reflex. 2009 , 1, S10-S14		5
132	Established medical therapy for benign prostatic hyperplasia. <i>Urologic Clinics of North America</i> , 2009 , 36, 443-59, v-vi	2.9	73
131	Alpha blockers prior to removal of a catheter for acute urinary retention in adult men. 2009 , CD006744		23
130	Acute Urinary Retention: How Useful is an Ambulatory Care Protocol?. 2009 , 16, 134-140		4
129	Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. 2010 , 33, 355-61		149
128	Alpha-blockers and intraoperative floppy iris syndrome: ophthalmic adverse events following cataract surgery. 2010 , 11, 242-8		5
127	The outcome of radical prostatectomy for patients with prostate cancer and acute urinary retention. 2010 , 4, 201-4		
126	The residual nonadrenergic contractile response to nerve stimulation of the mouse prostate is mediated by acetylcholine but not ATP in a comparison with the mouse vas deferens. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010 , 335, 489-96	4.7	10
125	Beta-adrenergic receptor blockade and prostate peptide growth factor expression in the rat. 2010 , 32, 105-109		1
124	The role of Doppler ultrasonography and resistive index in the diagnosis and treatment of benign prostate hyperplasia. 2010 , 36, 292-297		2

123	Division of prostatic anterior fibromuscular stroma reduces urethral resistance in an ex vivo human prostate model. 2010 , 76, 511.e10-3		6
122	Urinary Tract. 2011 ,		7
121	Hyperplasie bñigne de la prostate. 2011 , 4, 1-13		1
120	Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). 2011 , 163, 891-907		51
119	Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 339, 870-7	4-7	11
118	Muscarinic acetylcholine receptors in the urinary tract. 2011 , 319-44		34
117	[From lab to clinical activity: adrenergic receptors and human uro-genital tissues]. 2011 , 78, 153-60		
116	Animal models for benign prostatic hyperplasia. 2011 , 69-79		14
115	βBlockers for benign prostatic hyperplasia: the new era. 2012 , 22, 7-15		74
114	Analysis of energy loss mediated by an alpha-1 blocker in patients with benign prostatic hyperplasia using a virtual urethra processed from an endoscopic video image. 2012 , 26, 1216-20		5
113	Tamsulosin potently and selectively antagonizes human recombinant α(1A/1D)-adrenoceptors: slow dissociation from the α(1A)-adrenoceptor may account for selectivity for α(1A)-adrenoceptor over α(1B)-adrenoceptor subtype. 2012 , 35, 72-7		17
112	Hiperplasia benigna de la pròstata. 2012 , 44, 1-14		
111	Alpha adrenoceptor antagonists [have we reached the optimum balance of safety/efficacy?]. 2012 , 9, e27-e33		
110	[Update of the usefulness of βblockers in the treatment of different urologic pathologies]. 2012 , 139, 582-7		1
109	Peripheral Autonomic Pathways. 2012 , 141-185		6
108	Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms. 2012 , 12 Suppl 1, S22		6
107	Prostatic relaxation induced by agmatine is decreased in spontaneously hypertensive rats. 2012 , 110, E253-8		4
106	Rho kinase activation mediates adrenergic and cholinergic smooth muscle contractile responses in the mouse prostate gland. 2013 , 721, 313-21		9

105	Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression. 2013 , 9, 206-15	34
104	Localization of peripheral autonomic neurons innervating the boar urinary bladder trigone and neurochemical features of the sympathetic component. 2013 , 57, e16	22
103	Relaxing effect of acetylcholine on phenylephrine-induced contraction of isolated rabbit prostate strips is mediated by neuronal nitric oxide synthase. 2013 , 54, 333-8	1
102	The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. 2014 , CD006744	11
101	Cyclic guanosine monophosphate-enhancing reduces androgenic extracellular regulated protein kinases-phosphorylation/Rho kinase II-activation in benign prostate hyperplasia. 2014 , 21, 87-92	4
100	Editorial comment to role of male pelvic floor muscles and anterior fibromuscular stroma in males on α -blocker treatment: a magnetic resonance imaging study. 2014 , 21, 727-8	1
99	Lower urinary tract symptoms in men. 2014 , 349, g4474	41
98	WITHDRAWN: The impact of obesity towards prostate diseases. 2015 ,	
97	Tamsulosin modulates, but does not abolish the spontaneous activity in the guinea pig prostate gland. 2015 , 34, 482-8	6
96	Systematic review and meta-analysis on management of acute urinary retention. 2015 , 18, 297-302	19
95	The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. 2015 , 34, 286-93	52
94	Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia. 2015 , 85, 189-94	1
93	How close are PDE5 inhibitors to being successful in the treatment of BPH?. 2016 , 56, 381-2	
92	The impact of obesity towards prostate diseases. 2016 , 4, 1-6	46
91	Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review. 2016 , 33, 217-23	12
90	Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia. <i>Urologic Clinics of North America</i> , 2016 , 43, 311-23	2,9 25
89	Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochloride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. 2016 , 8, 38-43	9
88	Non-Adrenergic, Tamsulosin-Insensitive Smooth Muscle Contraction is Sufficient to Replace α -Adrenergic Tension in the Human Prostate. 2017 , 77, 697-707	17

87	Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome. 2017 , 98, 466-471	11
86	Inhibition of prostatic smooth muscle contraction by the inhibitor of G protein-coupled receptor kinase 2/3, CMPD101. 2018 , 831, 9-19	7
85	Drug Discovery in Japan. 2019 ,	3
84	Generation and Regulation of Spontaneous Contractions in the Prostate. 2019 , 1124, 195-215	2
83	A temporal and spatial map of axons in developing mouse prostate. 2019 , 152, 35-45	6
82	The role of anticholinergic therapy based on the upoint system in the treatment of chronic prostatitis. 2019 , 91, 16-21	1
81	New strategies for inhibition of non-adrenergic prostate smooth muscle contraction by pharmacologic intervention. 2019 , 79, 746-756	14
80	Ghrelin Aggravates Prostate Enlargement in Rats with Testosterone-Induced Benign Prostatic Hyperplasia, Stromal Cell Proliferation, and Smooth Muscle Contraction in Human Prostate Tissues. 2019 , 2019, 4748312	5
79	A study of prostate volumes in patients with spinal cord injury. 2019 , 38, 684-688	2
78	Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia-related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity. 2020 , 8, 152-157	2
77	Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α -blockers. 2020 , 873, 172985	5
76	Quantification of neural and hormonal receptors at the prostate of long-term sexual behaving male rats after lesion of pelvic and hypogastric nerves. 2020 , 222, 112915	
75	Molecular expression and functional features of Kv7 channels in human prostate smooth muscle. 2021 , 9, 933-943	
74	Men's Health for Hematopoietic Cell Transplant Patients. 2021 , 663-673	
73	The Autonomic Pharmacology of the Urinary Tract. 1984 , 5-30	3
72	Pharmacological Treatment of Benign Prostatic Hypertrophy. 1984 , 135-152	1
71	Obstructive and Functional Abnormalities I. 1986 , 235-275	5
70	Pharmacological Receptors in the Prostate. 1983 , 405-409	4

69	Dynamics of Acute Retention. 1983 , 497-501		5
68	α 1-Adrenoceptors in the urinary tract. 2011 , 283-306		20
67	Peripheral Autonomic Nervous System. 1990 , 93-123		9
66	Peripheral Autonomic Pathways. 2004 , 134-189		3
65	ETIOLOGY OF BENIGN PROSTATIC HYPERPLASIA. <i>Urologic Clinics of North America</i> , 1995 , 22, 237-246	2.9	58
64	ALPHA BLOCKADE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. <i>Urologic Clinics of North America</i> , 1995 , 22, 375-386	2.9	38
63	Embryologic Development of the Prostate: Insights into the Etiology and Treatment of Benign Prostatic Hyperplasia. <i>Urologic Clinics of North America</i> , 1990 , 17, 487-493	2.9	22
62	Alpha-Adrenergic Blockers for the Treatment of Benign Prostatic Hyperplasia. <i>Urologic Clinics of North America</i> , 1990 , 17, 641-649	2.9	72
61	Doxazosin for the Treatment of Benign Prostatic Hyperplasia in Patients with Mild to Moderate Essential Hypertension. 1995 , 110-115		7
60	Pharmacological Characterization of the Isolated Canine Prostate. 1996 , 1758-1761		1
59	INDUCTION OF PROSTATE APOPTOSIS BY DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA. 1998 , 1810-1815		4
58	Alpha1-adrenergic receptor subtypes in human detrusor. 1998 , 160, 937-43		59
57	NEW alpha 1-ADRENOCEPTOR ANTAGONIST, JTH-601, SHOWS MORE THAN 10 TIMES HIGHER AFFINITY FOR HUMAN PROSTATES THAN ARTERIES. 1999 , 1350-1354		0
56	CHARACTERIZATION AND FUNCTIONAL RELEVANCE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOENZYMES OF THE HUMAN PROSTATE. 2001 , 2484-2490		8
55	THE ROLE OF M2 MUSCARINIC RECEPTOR SUBTYPES IN MEDIATING CONTRACTION OF THE PIG BLADDER BASE AFTER CYCLIC ADENOSINE MONOPHOSPHATE ELEVATION AND/OR SELECTIVE M3 INACTIVATION. 2002 , 397-401		3
54	Applications of Quantitative Structure-Activity Relationships (QSAR) based Virtual Screening in Drug Design: A Review. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020 , 20, 1375-1388	3.2	11
53	Benign prostatic hyperplasia: An overview of existing treatment. 2011 , 43, 6-12		29
52	Acute urinary retention in benign prostatic hyperplasia: Risk factors and current management. 2007 , 23, 347-53		13

- 51 Medical Management for Benign Prostatic Hyperplasia. **2007**, 48, 233 4
- 50 Inhibition of human prostate smooth muscle contraction by the inhibitors of protein kinase C, GF109203X, and Go6983. **2022**, 82, 59-77 0
- 49 Pharmakologische Therapie. **2000**, 237-313
- 48 Urologika. **2000**, 561-578
- 47 Doxazosin for benign prostatic obstruction.
- 46 TISSUE SELECTIVITY OF KMD-3213, AN α_1 -ADRENOCEPTOR ANTAGONIST, IN HUMAN PROSTATE AND VASCULATURE. **2000**, 578-583 1
- 45 Urologika. **2001**, 682-701
- 44 Urologika. **2001**, 639-658
- 43 Urologika. **2004**, 807-830
- 42 Urologika. **2004**, 864-884
- 41 Controlled Release of Tamsulosin from Nanopore-Forming Granules. **2006**, 36, 39-44
- 40 Physiology and Pharmacology of the Prostate. **2011**, 239-248
- 39 Doxazosin for benign prostatic obstruction.
- 38 Non-Hormonal treatment of BPH/BOO. **2014**, 30, 194-201 1
- 37 The Pharmacology of Urinary Incontinence. **1984**, 419-440
- 36 Therapeutic Applications of Agents Interacting with alpha-1 Adrenergic Receptors. **1987**, 477-500
- 35 Nonsurgical Management of Vesicourethral Dysfunction. **1991**, 969-974
- 34 α -Adrenergic Blockade in the Treatment of Benign Prostatic Hyperplasia. **1993**, 173-182

33	Alpha blockade in the therapy of benign prostatic hyperplasia. 1993 , 505-513			1
32	Benign prostatic hyperplasia: pathogenesis and the role of medical management. 1993 , 495-504			
31	The Use of Pharmacologic Agents for Benign Prostatic Hyperplasia. 1994 , 193-204			
30	Localization of the alpha 1A-Adrenoceptor in the Human Prostate. 1995 , 2096-2099			
29	Nonsurgical Management of Vesicourethral Dysfunction. 1998 , 1233-1240			
28	Urologika. 1999 , 523-537			
27	Tradamixina TPIC Compound in Monotherapy for Three Months in Patients with LUTS: Observational Study on Improvement of Urinary Symptoms and Sexual Function in Men. <i>Health</i> , 2019 , 11, 621-629	0.4		0
26	Tamsulosin (Harnal, Flomax, OMNIC). 2019 , 111-125			
25	Medical Management of Benign Prostatic Hyperplasia. 2020 , 21-42			0
24	Treatment of Voiding LUTS. 2020 , 131-167			
23	Effect of Nonautonomic Drugs on the Vesical Neck. 1983 , 384-404			1
22	The response of the benign hypertrophied prostate to endocrine therapy. 1983 , 263-280			
21	Mechanisms of Autonomic Drug Action on the Bladder Outlet. 1983 , 373-383			1
20	Physiology and Pharmacology of the Prostate. 2020 , 127-150			1
19	Failure of Urinary Drainage: Lower Tract. 2007 , 118-131			1
18	Abnormalities of Ejaculation. <i>Urologic Clinics of North America</i> , 1987 , 14, 583-596	2.9		27
17	Effects of phenoxybenzamine on bladder neck opening. <i>Journal of the Royal Society of Medicine</i> , 1980 , 73, 345-7	2.3		
16	alpha-Blocker Therapy: Current Update. <i>Reviews in Urology</i> , 2005 , 7 Suppl 8, S34-42	1		3

15	The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. <i>Reviews in Urology</i> , 2006 , 8 Suppl 4, S3-9	1	14
14	Alpha blockers for the treatment of benign prostatic hyperplasia. <i>Reviews in Urology</i> , 2007 , 9, 181-90	1	71
13	Pharmacologic characteristics of bladder micturition function in anesthetized mice. <i>Comparative Medicine</i> , 2010 , 60, 436-42	1.6	1
12	Human prostate muscarinic receptor subtypes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1995 , 274, 976-82	4.7	42
11	The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT. <i>Anticancer Research</i> , 2015 , 35, 31-38	2.3	11
10	Impact of Adrenoceptor antagonists on prostate cancer development, progression and prevention. <i>American Journal of Clinical and Experimental Urology</i> , 2019 , 7, 46-60	1.6	5
9	and lactational 2,3,7,8-tetrachlorodibenzo-dioxin (TCDD) exposure exacerbates urinary dysfunction in hormone-treated C57BL/6J mice through a non-malignant mechanism involving proteomic changes in the prostate that differ from those elicited by testosterone and estradiol. <i>American Journal of Clinical and Experimental Urology</i> , 2020 , 8, 59-72	1.6	7
8	Male Lower Urinary Tract Dysfunction: An Underrepresented Endpoint in Toxicology Research.. <i>Toxics</i> , 2022 , 10,	4.7	
7	Altered small non-coding RNA expression profiles of extracellular vesicles in the prostatic fluid of patients with chronic pelvic pain syndrome.. <i>Experimental and Therapeutic Medicine</i> , 2022 , 23, 382	2.1	0
6	Static and dynamic component of obstruction in benign prostatic hyperplasia. 2022 , 1, 62-70		
5	A Concise and Useful Guide to Understand How Alpha1 Adrenoceptor Antagonists Work.. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022 ,	3.2	0
4	Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis. 2022 ,		0
3	RECENT PROGRESS IN THE PHARMACOTHERAPY OF DISEASES OF THE LOWER URINARY TRACT. 1995 , 30, 269s-298s		0
2	EXPANDING ROLE OF ALPHA ADRENOCEPTOR BLOCKADE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. 1998 , 52, 402-407		0
1	Electronic medical records-based retrospective, longitudinal, observational study to understand the patient management of benign prostatic hyperplasia with alpha-blockers monotherapy in Indian population. 2023 , 15, 138		0